Precision Therapeutics Inc. (AIPT) At $1.13 Forms Bottom; Cara Therapeutics (CARA) Shorts Raised By 4.87%

Cara Therapeutics, Inc. (NASDAQ:CARA) Logo

Cara Therapeutics Inc (NASDAQ:CARA) had an increase of 4.87% in short interest. CARA’s SI was 7.58M shares in July as released by FINRA. Its up 4.87% from 7.22 million shares previously. With 1.09M avg volume, 7 days are for Cara Therapeutics Inc (NASDAQ:CARA)’s short sellers to cover CARA’s short positions. The SI to Cara Therapeutics Inc’s float is 27.61%. The stock decreased 0.62% or $0.12 during the last trading session, reaching $19.15. About 991,168 shares traded. Cara Therapeutics, Inc. (NASDAQ:CARA) has risen 1.86% since July 1, 2017 and is uptrending. It has underperformed by 10.71% the S&P500. Some Historical CARA News: 10/05/2018 – CARA OPERATIONS LTD CARA.TO – QTRLY ADJUSTED DILUTED EPS $0.41; 10/05/2018 – CARA OPERATIONS – SYSTEM SALES GREW $96.8 MLN TO $755.9 MLN FOR 13 WEEKS ENDED APRIL 1, 2018 AS COMPARED TO 2017, REPRESENTING AN INCREASE OF 14.7%; 23/05/2018 – Cara Therapeutics Closes Above 200-Day Average: Technicals; 01/05/2018 – Cara Operations Closes Above 50-Day Moving Average: Technicals; 23/05/2018 – CARA THERAPEUTICS INC – CARA WILL SOLELY PROMOTE KORSUVA INJECTION IN ALL NON-FMC CLINICS IN U.S. AND RETAIN ALL PROFITS FROM THOSE SALES; 12/03/2018 – CARA OPERATIONS LTD CARA.TO : RBC RAISES TARGET PRICE TO C$32 FROM C$31; 09/05/2018 – Cara Therapeutics Expects Cash, Equivalents and Available-For-Sale Marketable Securities as of March 31 Will Be Sufficient to Fund Ops Into 1H 2019; 23/05/2018 – Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercializ; 23/03/2018 – People: Paris Jackson and Cara Delevingne ‘Have a Flirty Friendship’ but Aren’t Dating; 23/05/2018 – CARA THERAPEUTICS & VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (

Precision Therapeutics Inc. (AIPT) formed multiple bottom with $1.04 target or 8.00% below today’s $1.13 share price. Precision Therapeutics Inc. (AIPT) has $13.34 million valuation. The stock decreased 4.24% or $0.05 during the last trading session, reaching $1.13. About 313,070 shares traded or 9.89% up from the average. Precision Therapeutics Inc. (NASDAQ:AIPT) has declined 41.62% since July 1, 2017 and is downtrending. It has underperformed by 54.19% the S&P500.

More notable recent Cara Therapeutics, Inc. (NASDAQ:CARA) news were published by: Nasdaq.com which released: “Why Cara Therapeutics Stock Is Soaring Today” on June 27, 2018, also Seekingalpha.com with their article: “Cara Therapeutics: Worth Keeping An Eye On” published on June 28, 2018, Nasdaq.com published: “Mid-Afternoon Market Update: US Stocks Turn Negative; Cara Therapeutics Shares Spike Higher” on June 27, 2018. More interesting news about Cara Therapeutics, Inc. (NASDAQ:CARA) were released by: Nasdaq.com and their article: “Cara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of IV CR845 in Patients Undergoing …” published on June 27, 2018 as well as Nasdaq.com‘s news article titled: “Where Will Cara Therapeutics, Inc. Be in 5 Years?” with publication date: June 07, 2018.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $626.20 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The companyÂ’s lead product candidate comprises I.V.

Among 6 analysts covering Cara Therapeutics (NASDAQ:CARA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cara Therapeutics had 10 analyst reports since January 2, 2018 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, January 2. The firm has “Buy” rating given on Wednesday, May 23 by H.C. Wainwright. On Thursday, May 24 the stock rating was maintained by Laidlaw with “Buy”. Canaccord Genuity maintained it with “Buy” rating and $22.0 target in Thursday, March 15 report. H.C. Wainwright maintained it with “Buy” rating and $22.0 target in Monday, March 19 report. The company was upgraded on Monday, February 12 by Janney Capital. The rating was reinitiated by H.C. Wainwright with “Buy” on Monday, March 12. On Friday, May 11 the stock rating was maintained by H.C. Wainwright with “Buy”. On Friday, June 29 the stock rating was maintained by Canaccord Genuity with “Buy”.

Investors sentiment decreased to 0.83 in Q1 2018. Its down 0.10, from 0.93 in 2017Q4. It worsened, as 13 investors sold Cara Therapeutics, Inc. shares while 27 reduced holdings. 15 funds opened positions while 18 raised stakes. 15.62 million shares or 1.17% less from 15.80 million shares in 2017Q4 were reported. Manufacturers Life Ins The holds 21,291 shares. Jpmorgan Chase & has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Hightower Advisors Ltd Liability has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA). Citadel Advsrs has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Tci Wealth Advsr accumulated 175 shares or 0% of the stock. Tiverton Asset Mngmt Limited Liability Company reported 0.01% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Vanguard Gp has 1.23M shares. Citigroup stated it has 26,153 shares. Us Savings Bank De reported 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). 4,089 are owned by Royal Bancorporation Of Canada. Barclays Plc holds 8,102 shares. Sei Invs holds 0% in Cara Therapeutics, Inc. (NASDAQ:CARA) or 125 shares. Voya Invest Mgmt Ltd Com stated it has 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Bridgeway Cap holds 55,000 shares or 0.01% of its portfolio. Horrell Capital Inc holds 0% in Cara Therapeutics, Inc. (NASDAQ:CARA) or 400 shares.

Cara Therapeutics, Inc. (NASDAQ:CARA) Institutional Positions Chart